Introduction:Stool DNA testing based on methylated syndecan-2(mSDC2)is a potential novel non-invasive screening test for colorectal cancer(CRC).This study aimed to assess its positive predictive value(PPV)in real-worl...Introduction:Stool DNA testing based on methylated syndecan-2(mSDC2)is a potential novel non-invasive screening test for colorectal cancer(CRC).This study aimed to assess its positive predictive value(PPV)in real-world practice.Methods:This study retrospectively recruited consecutive patients with positive stool DNA-based SDC2 methylation tests from 18 hospitals between November 2016 and July 2021.Included patients were classified into the average-risk equivalent or increased-risk population and the previous-negative-colonoscopy or no-previous-colonoscopy groups.Multivariate logistic regression was conducted to investigate the risk factors that affect the detection of advanced colorectal neoplasia(ACN)in patients with a positive mSDC2 test.The primary outcome was the PPV for ACN.Results:The overall PPVs for ACN,CRC,and colorectal neoplasia were 28.5%,12.8%,and 44.6%,respectively.The PPV for ACN was higher in the no-previous-colonoscopy group than in the previous-negative-colonoscopy group(30.1%vs 18.5%,P=0.008)and higher in the increased-risk population than in the average-risk equivalent population(41.1%vs 21.6%,P<0.001).However,the PPV(18.5%)was still high for patients with a previous negative colonoscopy.For ACN detection in patients with a positive mSDC2 test,old age,increased risk,and smoking history were identified as independent risk factors;previous negative colonoscopy was identified as a protective factor.Conclusions:The mSDC2 test,which has a high PPV for both ACN and CRC,is expected to be an alternative CRC screening strategy.Patients with a positive mSDC2 test might require a colonoscopy as soon as possible,even if the previous colonoscopy was negative.展开更多
基金Noncommunicable Chronic Diseases-National Science and Technology Major Project(No.2023ZD0501600)Changhai Hospital Special Foundation for Clinical Research Program(No.2024LYB05)+5 种基金the China National Postdoctoral Program for Innovative Talents(No.BX20230482)Chenguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education Commission(Grant No.22CGA42)Natural Science Foundation of Shanghai(No.23ZR1478700)Shanghai Sailing Program(No.23YF1458600)Shanghai Eastern Talent Youth Program(QNWS2024108)Changfeng Guhai Project of Changying Youth Seedling Plan of Changhai Hospital.
文摘Introduction:Stool DNA testing based on methylated syndecan-2(mSDC2)is a potential novel non-invasive screening test for colorectal cancer(CRC).This study aimed to assess its positive predictive value(PPV)in real-world practice.Methods:This study retrospectively recruited consecutive patients with positive stool DNA-based SDC2 methylation tests from 18 hospitals between November 2016 and July 2021.Included patients were classified into the average-risk equivalent or increased-risk population and the previous-negative-colonoscopy or no-previous-colonoscopy groups.Multivariate logistic regression was conducted to investigate the risk factors that affect the detection of advanced colorectal neoplasia(ACN)in patients with a positive mSDC2 test.The primary outcome was the PPV for ACN.Results:The overall PPVs for ACN,CRC,and colorectal neoplasia were 28.5%,12.8%,and 44.6%,respectively.The PPV for ACN was higher in the no-previous-colonoscopy group than in the previous-negative-colonoscopy group(30.1%vs 18.5%,P=0.008)and higher in the increased-risk population than in the average-risk equivalent population(41.1%vs 21.6%,P<0.001).However,the PPV(18.5%)was still high for patients with a previous negative colonoscopy.For ACN detection in patients with a positive mSDC2 test,old age,increased risk,and smoking history were identified as independent risk factors;previous negative colonoscopy was identified as a protective factor.Conclusions:The mSDC2 test,which has a high PPV for both ACN and CRC,is expected to be an alternative CRC screening strategy.Patients with a positive mSDC2 test might require a colonoscopy as soon as possible,even if the previous colonoscopy was negative.
